Blue Earth Diagnostics is an established molecular imaging company that specializes in developing precision radiopharmaceuticals for patients with cancer. As a global leader in the field, their mission is to provide innovative and well-differentiated diagnostic solutions that inform patients and drive future therapies in cancer. With a strong focus exclusively on cancer, Blue Earth Diagnostics applies their knowledge and expertise to develop promising radiopharmaceuticals for imaging, empowering the evolution of care for patients with cancer.

Founded in 2014, Blue Earth Diagnostics has quickly gained recognition for its management expertise, agility, and rapid development and commercialization of PET radiopharmaceuticals. Their products and technologies have been widely adopted, including the diagnostic PET molecular imaging agent, Axumin®, and the recently approved POSLUMA® (flotufolastat F 18) Injection. Blue Earth Diagnostics is committed to advancing the field of molecular imaging and improving patient outcomes in collaboration with healthcare professionals, research partnerships, and healthcare providers worldwide